Cellectis (Cellectis) Total Assets : $209.70 Mil (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Cellectis Total Assets?

Cellectis's Total Assets for the quarter that ended in Sep. 2023 was $209.70 Mil.

Warning Sign:

If a company builds assets at 44.4% a year, faster than its revenue growth rate of 4.2% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Cellectis's average Total Assets Growth Rate was -17.80% per year. During the past 3 years, the average Total Assets Growth Rate was 17.20% per year. During the past 5 years, the average Total Assets Growth Rate was 44.40% per year. During the past 10 years, the average Total Assets Growth Rate was 21.90% per year.

During the past 13 years, Cellectis's highest 3-Year average Total Assets Growth Rate was 76.00%. The lowest was -24.80%. And the median was 21.10%.

Total Assets is connected with ROA %. Cellectis's annualized ROA % for the quarter that ended in Sep. 2023 was -31.98%. Total Assets is also linked to Revenue through Asset Turnover. Cellectis's Asset Turnover for the quarter that ended in Sep. 2023 was 0.00.

Cellectis Total Assets Historical Data

The historical data trend for Cellectis's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Total Assets Chart

Cellectis Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Assets

Get a 7-Day Free Trial

500.84

467.47

469.47

382.08

261.22

Cellectis Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Assets	Get a 7-Day Free Trial															279.58	261.22	251.41	227.67	209.70

Cellectis Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Cellectis's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets	=	Total Equity (A: Dec. 2022 )	+	Total Liabilities (A: Dec. 2022 )
	=	125.941	+	135.275
	=	261.22

Cellectis's Total Assets for the quarter that ended in Sep. 2023 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2023 )	+	Total Liabilities (Q: Sep. 2023 )
	=	76.123	+	133.577
	=	209.70

Cellectis (NAS:CLLS) Total Assets Explanation

Total Assets is connected with ROA %.

Cellectis's annualized ROA % for the quarter that ended in Sep. 2023 is

ROA %	=	Net Income (Q: Sep. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
	=	-69.928	/	( (227.674	+	209.7)	/ 2 )
	=	-69.928	/	218.687
	=	-31.98 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Cellectis's Asset Turnover for the quarter that ended in Sep. 2023 is

	Asset Turnover
=	Revenue (Q: Sep. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
=	0.155	/	( (227.674	+	209.7)	/ 2 )
=	0.155	/	218.687
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Cellectis Total Assets Related Terms

Thank you for viewing the detailed overview of Cellectis's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectis (Cellectis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

CMVLF:USA 0WA2:UK ALCLS:France ZVAA:Germany

Address

8, rue de la Croix Jarry, Paris, FRA, 75013

Website

https://www.cellectis.com

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.